AI + blood test could spot lung cancer earlier in smokers
NCT ID NCT06320184
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether combining artificial intelligence with blood biomarkers and CT scan features can better predict lung cancer risk in heavy smokers. Researchers will analyze data from 650 participants to develop a risk model that improves screening accuracy and reduces unnecessary follow-ups. The goal is to make lung cancer screening more precise and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Artificial intelligence risk model combining blood biomarkers, radiologic parameters, and clinical features
What this could lead to
If successful, this could lead to a more accurate, non-invasive way to identify who is at high risk for lung cancer, reducing unnecessary procedures and catching cancers earlier.
What could go wrong
This is an observational study, not a treatment trial. The AI model may not perform as well in real-world settings, and results may take years to validate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy